Nutron Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 16-06-2024
- Paid Up Capital ₹ 0.48 M
as on 16-06-2024
- Company Age 34 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 15.00 Cr
as on 16-06-2024
- Satisfied Charges ₹ 26.94 Cr
as on 16-06-2024
- Revenue -37.72%
(FY 2023)
- Profit -49.46%
(FY 2023)
- Ebitda -63.43%
(FY 2023)
- Net Worth 8.70%
(FY 2023)
- Total Assets 11.18%
(FY 2023)
About Nutron Pharmaceuticals
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.48 M.
The company currently has active open charges totaling ₹15.00 Cr. The company has closed loans amounting to ₹26.94 Cr, as per Ministry of Corporate Affairs (MCA) records.
Dinesh Shah, Jayesh Shah, Ramesh Shah, and Four other members serve as directors at the Company.
- CIN/LLPIN
U24230MH1990PTC058515
- Company No.
058515
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Oct 1990
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Nutron Pharmaceuticals?
Board Members(7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Praful Shah  | Director | 18-Oct-2012 | Current |
| Dinesh Shah | Director | 15-Mar-1999 | Current |
| Jayesh Shah | Director | 15-Mar-1999 | Current |
| Ramesh Shah | Director | 12-Oct-1990 | Current |
| Manish Shah | Director | 03-Apr-1995 | Current |
| Popatlal Shah | Director | 12-Oct-1990 | Current |
Financial Performance of Nutron Pharmaceuticals.
Nutron Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 37.72% decrease. The company also saw a substantial fall in profitability, with a 49.46% decrease in profit. The company's net worth moved up by a moderate rise of 8.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nutron Pharmaceuticals?
In 2023, Nutron Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Terrapolis Buildcon Private LimitedActive 12 years 4 monthsJayesh Shah, Manish Shah and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 Jan 2021 | ₹15.00 Cr | Open |
Citi Bank N.A. Creation Date: 15 Feb 2008 | ₹22.50 Cr | Satisfied |
Citibank N.A. Creation Date: 05 Mar 2007 | ₹2.50 Cr | Satisfied |
How Many Employees Work at Nutron Pharmaceuticals?
Unlock and access historical data on people associated with Nutron Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nutron Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nutron Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
